Death Incidents Following Transcatheter Edge-to-edge Repair (TEER) with the MitraClip Device: Analysis of 10-years Post-marketing Death Reports from the Manufacturer and User Facility Device Experience (MAUDE) Registry

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Date 2025 Jan 10

PMID 39794724

Authors

Xinghe Sun

Yifei Zhao

Yan Li

Affiliations

Soon will be listed here.

Abstract

Background: The transcatheter edge-to-edge repair (TEER) technique, facilitated by the MitraClip device, is a minimally invasive intervention designed for high-risk patients with mitral regurgitation (MR). This study conducts a retrospective analysis of death events associated with MitraClip implantation over a ten-year decade, utilizing data from the FDA's Manufacturer and User Facility Device Experience (MAUDE) database to evaluate trends in safety outcomes.

Methods: A comprehensive search of the publicly accessible MAUDE database was conducted to retrieve reports of deaths and injuries related to MitraClip implantation from October 2013 to September 2023. Duplicate reports and records from unrelated sources were excluded. The Cochran-Armitage test was performed to evaluate trends in the proportion of fatal events over time.

Results: During the 10-year period following FDA approval, the MAUDE database recorded a total of 927 death reports and 9,211 injury reports associated with MitraClip. After excluding duplicates and irrelevant reports, 592 death cases were analyzed. The most commonly reported complications were MR (26.69%), tissue damage (24.16%), and hypotension (22.13%). The most frequent device-related issues were incomplete coaptation (14.70%), difficulty removing the divice (6.42%), and failure to adhere or bond/positioning failure(4.90%). Notably, 76.94% of deaths occurred within one year of implantation. The proportion of fatal events demonstrated a gradual decline, from 15.9% in 2014-2015 to 3.5% in 2020-2021 (p < 0.0001).

Conclusions: This analysis of the MAUDE database indicates a gradual decline in the proportion of fatal events associated with MitraClip implantation, which may be attributed to growing operator experience and advancements in device design. Nonetheless, persistent focus is required on managing complications and addressing potential risks to further enhance device performance and optimize its clinical utility.

References

Nishiura N, Kubo S, Fujita M, Mushiake K, Ono S, Osakada K . Indications and outcomes of the MitraClip G4 device with controlled gripper actuation system. Cardiovasc Interv Ther. 2024; 39(4):468-478. DOI: 10.1007/s12928-024-01018-0. View

Perlowski A, St Goar F, Glower D, Feldman T . Percutanenous therapies for mitral regurgitation. Curr Probl Cardiol. 2012; 37(2):42-68. DOI: 10.1016/j.cpcardiol.2011.09.001. View

Sugiura A, Kavsur R, Spieker M, Iliadis C, Goto T, Ozturk C . Recurrent Mitral Regurgitation After MitraClip: Predictive Factors, Morphology, and Clinical Implication. Circ Cardiovasc Interv. 2022; 15(3):e010895. DOI: 10.1161/CIRCINTERVENTIONS.121.010895. View

Panaich S, Eleid M . Current status of MitraClip for patients with mitral and tricuspid regurgitation. Trends Cardiovasc Med. 2017; 28(3):200-209. DOI: 10.1016/j.tcm.2017.08.008. View

Anker S, Friede T, von Bardeleben R, Butler J, Fatima K, Diek M . Randomized investigation of the MitraClip device in heart failure: Design and rationale of the RESHAPE-HF2 trial design. Eur J Heart Fail. 2024; 26(4):984-993. DOI: 10.1002/ejhf.3247. View

Hausleiter J, Stocker T, Adamo M, Karam N, Swaans M, Praz F . Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023; 18(12):957-976. PMC: 9869401. DOI: 10.4244/EIJ-D-22-00725. View

Chakravarty T, Makar M, Patel D, Oakley L, Yoon S, Stegic J . Transcatheter Edge-to-Edge Mitral Valve Repair With the MitraClip G4 System. JACC Cardiovasc Interv. 2020; 13(20):2402-2414. DOI: 10.1016/j.jcin.2020.06.053. View

Ling L, Enriquez-Sarano M, Seward J, Tajik A, Schaff H, Bailey K . Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med. 1996; 335(19):1417-23. DOI: 10.1056/NEJM199611073351902. View

Enriquez-Sarano M, Akins C, Vahanian A . Mitral regurgitation. Lancet. 2009; 373(9672):1382-94. DOI: 10.1016/S0140-6736(09)60692-9. View

10.

Dodoo S, Okoh A, Oseni A, Odiete O, Okafor H . Adverse Events Following Transcatheter Edge-to-Edge Repair (TEER) Using MitraClip: Lessons Learned From the Manufacturer and User Facility Device Experience (MAUDE) Registry. Cardiovasc Revasc Med. 2021; 39:101-105. PMC: 10895476. DOI: 10.1016/j.carrev.2021.09.007. View

11.

Alegria-Barrero E, Franzen O . Mitral Regurgitation - A Multidisciplinary Challenge. Eur Cardiol. 2018; 9(1):49-53. PMC: 6159436. DOI: 10.15420/ecr.2014.9.1.49. View

12.

Qintar M, Chhatriwalla A . Update on the Current Status and Indications for Transcatheter Edge-to-Edge Mitral Valve Repair. Curr Cardiol Rep. 2020; 22(11):135. DOI: 10.1007/s11886-020-01391-1. View

13.

Minha S, Torguson R, Waksman R . Overview of the 2013 Food and Drug Administration Circulatory System Devices Panel meeting on the MitraClip Delivery System. Circulation. 2013; 128(8):864-8. DOI: 10.1161/CIRCULATIONAHA.113.004062. View

14.

Hosseini K, Soleimani H, Nasrollahizadeh A, Jenab Y, Karlas A, Avgerinos D . Edge-to-Edge Transcatheter Mitral Valve Repair Using PASCAL vs. MitraClip: A Systematic Review and Meta-Analysis. J Clin Med. 2023; 12(10). PMC: 10219028. DOI: 10.3390/jcm12103579. View

15.

Khurrami S, Koll B, Ludwig S, Pauschinger C, Weimann J, Reichenspurner H . Differential effects of anaemia and iron deficiency on long-term outcomes following transcatheter edge-to-edge repair in degenerative vs. secondary mitral regurgitation: results from a large single-center study. Clin Res Cardiol. 2023; 112(7):967-980. DOI: 10.1007/s00392-023-02210-7. View

16.

Nkomo V, Gardin J, Skelton T, Gottdiener J, Scott C, Enriquez-Sarano M . Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368(9540):1005-11. DOI: 10.1016/S0140-6736(06)69208-8. View

17.

Anker S, Friede T, von Bardeleben R, Butler J, Khan M, Diek M . Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. N Engl J Med. 2024; 391(19):1799-1809. DOI: 10.1056/NEJMoa2314328. View

18.

Phillips H, Levine F, Carter J, Boucher C, Osbakken M, Okada R . Mitral valve replacement for isolated mitral regurgitation: analysis of clinical course and late postoperative left ventricular ejection fraction. Am J Cardiol. 1981; 48(4):647-54. DOI: 10.1016/0002-9149(81)90142-9. View

19.

Rudolph F, Kirchner J, Ivannikova M, Fortmeier V, Rudolph T, Friedrichs K . A Comparative Study of 1-Year Postprocedural Outcomes in Transcatheter Mitral Valve Repair in Advanced Primary Mitral Regurgitation: PASCAL vs. MitraClip. J Clin Med. 2024; 13(2). PMC: 10816098. DOI: 10.3390/jcm13020484. View

20.

Grayburn P, Sannino A, Packer M . Proportionate and Disproportionate Functional Mitral Regurgitation: A New Conceptual Framework That Reconciles the Results of the MITRA-FR and COAPT Trials. JACC Cardiovasc Imaging. 2018; 12(2):353-362. DOI: 10.1016/j.jcmg.2018.11.006. View